Prosecution Insights
Last updated: October 27, 2026

Sue Xu Liu, USPTO Patent Examiner

Listed by the USPTO as LIU, SUE XU

Tech Center 1600 • Art Units: 1616 1623 1639 1643 1645 1646 1653 1654

This examiner grants 21% of resolved cases

Analysis

Sue Xu Liu has 239 resolved cases in Art Unit 1616. The allowance rate for these cases is 20.9%. The median time to allowance is 1614 days. The interview lift is 18.6%, which represents the change in allowance probability after an interview. These statistics define the prosecution environment in Tech Center 1600.

Toray Industries Inc., Novartis AG, and DISCOVERY PURCHASER CORPORATION are the top companies in this examiner's record. The 20.9% allowance rate and the 1614-day median pendency are the primary metrics for these applicants. Firms like COOLEY LLP, BIRCH STEWART KOLASCH & BIRCH, LLP, and NIXON & VANDERHYE, PC are active in this queue.

The 18.6% interview lift indicates that interviews correlate with a higher probability of allowance. Practitioners can use the 1614-day median time to allowance to estimate the duration of the prosecution process. The 20.9% allowance rate provides a baseline for the likelihood of success. The 239 resolved cases offer a specific view of the examiner's historical performance.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

20.9%
Allow Rate
-39.1% vs TC avg
303
Total Applications
+18.6%
Interview Lift
1614
Avg Prosecution Days
Based on 239 resolved cases, 2023–2026

Rejection Statute Breakdown

2.6%
§101 Eligibility
14.5%
§102 Novelty
42.3%
§103 Obviousness
27.6%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18569346 PHARMACEUTICAL FORMULATION CONTAINING AN ANTI-IgE ANTIBODY Non-Final OA NOVARTIS AG
18292078 MEDICAMENT FOR TREATMENT AND/OR PREVENTION OF CANCER Non-Final OA TORAY INDUSTRIES, INC.
17910522 MEDICAMENT FOR TREATMENT AND/OR PREVENTION OF CANCER Non-Final OA TORAY INDUSTRIES, INC.
18555070 RETINOL FORMULATION (II) Non-Final OA DSM IP ASSETS B.V.
17814198 T CELLS EXPRESSING MEMBRANE-ANCHORED IL-12 FOR THE TREATMENT OF CANCER Non-Final OA Board of Regents, The University of Texas System
18134993 COMPOSITIONS INCLUDING ENDOPHYTES FOR IMPROVING PLANT NUTRITION, GROWTH,AND PERFORMANCE AND METHODS OF USING THE SAME Non-Final OA University of Washington
17907313 INDUCING PRODUCTION OF ANTI-OLIGOMANNOSE ANTIBODIES Non-Final OA SRI International
17908497 COMPOSITIONS AND METHODS FOR REPELLING ANIMALS FROM AN OBJECT Final Rejection Texas Tech University System
18563440 ANTIBODIES Non-Final OA Oxford University Innovation Limited

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Who Appears Before This Examiner

Top companies before this examiner

Law firms appearing most often

Frequently Asked Questions

What is examiner Sue Xu Liu's allowance rate?

20.9% of resolved applications examined by Sue Xu Liu were allowed (239 resolved cases), compared with 24.5% across Art Unit 1616 over the last five years.

Does an interview help with examiner Sue Xu Liu?

This examiner's interview lift is +18.6 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.

How long does examiner Sue Xu Liu take to allow a patent?

Applications allowed by Sue Xu Liu took 1,614 days on average from filing to allowance.

Which art unit does examiner Sue Xu Liu work in?

Sue Xu Liu examines applications in Art Unit 1616 in Tech Center 1600 (Biotechnology & Pharmaceuticals).

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month